Variety of clinical manifestations of hypertriglyceridemia: a case series
V. K. Zafiraki,
A. M. Namitokov,
I. V. Gilevich,
M. V. Gradovskaya,
O. V. Malyarevskaya,
K. V. Karabakhtsieva https://doi.org/10.15829/1560-4071-2023-5545
EDN: OOJFQW
Abstract
To date, there is no doubt about the participation of triglyceride-rich lipoproteins in atherogenesis. However, the variety of clinical manifestations of hypertriglyceridemia does not always allow timely recognition of patients with high cardiovascular risk for the timely initiation of therapy. The article presents 3 following cases: patient with isolated hypertriglyceridemia without clinical manifestations and with a good response to treatment, a patient with skin manifestations of hypertriglyceridemia and a patient with severe multifocal atherosclerosis, diabetes and recurrent pancreatitis. References are also provided for each case.
Supporting agencies: The study was supported by the Kuban Science Foundation within the scientific project № MFI-20.1/63
About the Authors
V. K. Zafiraki
Kuban State Medical University
Russian Federation
Competing Interests:
Russian Federation
Krasnodar
Competing Interests:
none
A. M. Namitokov
Kuban State Medical University; Research Institute — S. V. Ochapovsky Regional Clinical Hospital № 1
Russian Federation
Competing Interests:
Russian Federation
Krasnodar
Competing Interests:
none
I. V. Gilevich
Kuban State Medical University; Research Institute — S. V. Ochapovsky Regional Clinical Hospital № 1
Russian Federation
Competing Interests:
Russian Federation
Krasnodar
Competing Interests:
none
M. V. Gradovskaya
Research Institute — S. V. Ochapovsky Regional Clinical Hospital № 1
Russian Federation
Competing Interests:
Russian Federation
Krasnodar
Competing Interests:
none
O. V. Malyarevskaya
Research Institute — S. V. Ochapovsky Regional Clinical Hospital № 1
Russian Federation
Competing Interests:
Russian Federation
Krasnodar
Competing Interests:
none
K. V. Karabakhtsieva
Kuban State Medical University
Russian Federation
Competing Interests:
Russian Federation
Krasnodar
Competing Interests:
none
References
1. Karpov Y., Khomitskaya Y. PROMETHEUS: an observational, cross-sectional, retrospective study of hypertriglyceridemia in Russia. Cardiovasc Diabetol. 2015; 14: 115. doi:10.1186/s12933-015-0268-2
2. Ruiz-García A, Arranz-Martínez E, López-Uriarte B, et al. Prevalence of hypertriglyceridemia in adults and related cardiometabolic factors. SIMETAP-HTG study. Clin Investig Arterioscler. 2020 Nov-Dec;32(6):242-255. English, Spanish. doi: 10.1016/j.arteri.2020.04.001
3. Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021 Dec 14;42(47):4791-4806. doi: 10.1093/eurheartj/ehab551
4. Brunzell JD, Schrott HG. The interaction of familial and secondary causes of hypertriglyceridemia: role in pancreatitis. J Clin Lipidol 2012;6:409–412.
5. Hegele RA, Ginsberg HN, Chapman MJ et al. European Atherosclerosis Society Consensus Panel. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014 Aug;2(8):655-66. doi: 10.1016/S2213-8587(13)70191-8. Epub 2013 Dec 23. PMID: 24731657; PMCID: PMC4201123
6. Flynn PD. Xanthomas and abnormalities of lipid metabolism and storage. In: Griffiths C, Barker J, Bleiker T, Chalmers R, Creamer D (eds). Rook’s Textbook of Dermatology [4 volumes], 9th edn. Wiley Blackwell, 2016: 62.2-6
7. Zak A, Zeman M, Slaby A, Vecka M. Xanthomas: Clinical and pathophysiological relations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014;158:181–8.
8. Parker F, Odland GF. Ultrastructural and lipid biochemical comparisons of human eruptive, tuberous and planar xanthomas. Isr J Med Sci. 1973 Apr;9(4):395-423. PMID: 4350832
9. Havel RJ. Pathogenesis, differentiation and management of hypertriglyceridemia. Adv Intern Med. 1969;15:117-54. PMID: 4908616.
10. Brunzell JD, Schrott HG. The interaction of familial and secondary causes of hypertriglyceridemia: role in pancreatitis. Trans Assoc Am Physicians. 1973;86:245-54. PMID: 4788799.
11. Fallat RW, Vester JW, Glueck CJ. Suppression of amylase activity by hypertriglyceridemia. JAMA. 1973 Sep 10;225(11):1331-4. PMID: 4740657
12. Viikari J, Ruuskanen O, Nikkari T, Kouvalainen K. Hypertriglyseridemia ja pankreatiitti [Hypertriglyceridemia and pancreatitis]. Duodecim. 1974;90(18):1235-41. Finnish. PMID: 4370979
13. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188. DOI: 10.1093/eurheartj/ehz455
14. Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. Eur Heart J. 2020;41:99–109c. doi: 10.1093/eurheartj/ehz785
15. Yadav D., Pitchumoni C.S. Issues in hyperlipidemic pancreatitis. J Clin Gastroenterol. 2003 Jan; 36(1): 54-62
Supplementary files
Review
For citations:
Zafiraki V.K., Namitokov A.M., Gilevich I.V., Gradovskaya M.V., Malyarevskaya O.V., Karabakhtsieva K.V. Variety of clinical manifestations of hypertriglyceridemia: a case series. Russian Journal of Cardiology. 2023;28(3S):5545. (In Russ.) https://doi.org/10.15829/1560-4071-2023-5545. EDN: OOJFQW
Views:
718
Email this article 